Inovio Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Inovio Pharmaceuticals (INO) shares plummeted 36.92% to $0.66 on Thursday, significantly underperforming the broader market and its competitors like Johnson & Johnson and Pfizer. This drop ended a two-day winning streak and left the stock 77.98% below its 52-week high of $2.98. Trading volume surged to 33.3 million, far exceeding the 50-day average of 1.8 million.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Inovio Pharmaceuticals Inc. (INO) cratered 36.92% to $0.66 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 2.78% to 25,122.18 and the Dow Jones Industrial Average rising 1.19% to 52,208.06.
The stock's fall snapped a two-day winning streak.
Inovio Pharmaceuticals Inc. closed 77.98% short of its 52-week high of $2.98, which the company reached on September 9th.
The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson (JNJ) fell 3.66% to $255.82, Statera Biopharma Inc. (STAB) remained unchanged, and Pfizer Inc. (PFE) fell 0.95% to $24.91.
Trading volume (33.3 M) eclipsed its 50-day average volume of 1.8 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 30, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-30-26 1726ET